NASDAQ:BYSI

BeyondSpring Competitors

$10.29

-0.33 (-3.11 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.15

Now: $10.29▼

$10.75

50-Day Range

$10.27

MA: $12.26▼

$14.92

52-Week Range

$9.83

Now: $10.29▼

$21.50

Volume140,238 shs

Average Volume275,148 shs

Market Capitalization$402.77 million

P/E RatioN/A

Dividend YieldN/A

Beta0.6

BeyondSpring (NASDAQ:BYSI) Vs. TVTX, ZNTL, GBIO, KRON, QURE, and HRTX

Should you be buying BYSI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BeyondSpring, including Travere Therapeutics (TVTX), Zentalis Pharmaceuticals (ZNTL), Generation Bio (GBIO), Kronos Bio (KRON), uniQure (QURE), and Heron Therapeutics (HRTX).

BeyondSpring vs. Travere Therapeutics Stock

BeyondSpring (NASDAQ:BYSI) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Travere Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	-221.67%	-139.97%
Travere Therapeutics	-40.24%	-29.27%	-12.25%

Valuation & Earnings

This table compares BeyondSpring and Travere Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	$-38,080,000.00	($1.55)	-6.64
Travere Therapeutics	$175.34 million	8.83	$-146,430,000.00	($3.46)	-7.40

BeyondSpring has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

BeyondSpring has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Travere Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	0	1	2	0	2.67
Travere Therapeutics	0	0	4	0	3.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Travere Therapeutics has a consensus target price of $47.00, suggesting a potential upside of 83.52%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Travere Therapeutics.

Summary

Travere Therapeutics beats BeyondSpring on 7 of the 13 factors compared between the two stocks.

BeyondSpring vs. Zentalis Pharmaceuticals Stock

BeyondSpring (NASDAQ:BYSI) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	-221.67%	-139.97%
Zentalis Pharmaceuticals	N/A	N/A	N/A

Valuation & Earnings

This table compares BeyondSpring and Zentalis Pharmaceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	$-38,080,000.00	($1.55)	-6.64
Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Zentalis Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	0	1	2	0	2.67
Zentalis Pharmaceuticals	0	0	7	0	3.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Zentalis Pharmaceuticals has a consensus target price of $54.2857, suggesting a potential upside of 45.11%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Zentalis Pharmaceuticals.

Summary

Zentalis Pharmaceuticals beats BeyondSpring on 5 of the 6 factors compared between the two stocks.

BeyondSpring vs. Generation Bio Stock

BeyondSpring (NASDAQ:BYSI) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Generation Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	-221.67%	-139.97%
Generation Bio	N/A	N/A	N/A

Valuation & Earnings

This table compares BeyondSpring and Generation Bio's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	$-38,080,000.00	($1.55)	-6.64
Generation Bio	N/A	N/A	N/A	N/A	N/A

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Generation Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	0	1	2	0	2.67
Generation Bio	0	0	6	0	3.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Generation Bio has a consensus target price of $40.60, suggesting a potential upside of 49.26%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Generation Bio.

Summary

Generation Bio beats BeyondSpring on 5 of the 6 factors compared between the two stocks.

BeyondSpring vs. Kronos Bio Stock

BeyondSpring (NASDAQ:BYSI) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and Kronos Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	-221.67%	-139.97%
Kronos Bio	N/A	N/A	N/A

Valuation & Earnings

This table compares BeyondSpring and Kronos Bio's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	$-38,080,000.00	($1.55)	-6.64
Kronos Bio	N/A	N/A	N/A	N/A	N/A

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Kronos Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	0	1	2	0	2.67
Kronos Bio	0	0	4	0	3.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 60.07%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Kronos Bio.

Summary

Kronos Bio beats BeyondSpring on 4 of the 6 factors compared between the two stocks.

BeyondSpring vs. uniQure Stock

BeyondSpring (NASDAQ:BYSI) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BeyondSpring and uniQure's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	-221.67%	-139.97%
uniQure	-2,738.33%	-59.64%	-41.47%

Valuation & Earnings

This table compares BeyondSpring and uniQure's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	$-38,080,000.00	($1.55)	-6.64
uniQure	$7.28 million	208.53	$-124,200,000.00	($3.11)	-10.85

BeyondSpring has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 78.3% of uniQure shares are held by institutional investors. 2.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

BeyondSpring has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and uniQure, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	0	1	2	0	2.67
uniQure	0	1	11	1	3.00

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. uniQure has a consensus target price of $68.4615, suggesting a potential upside of 102.91%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than uniQure.

Summary

uniQure beats BeyondSpring on 9 of the 14 factors compared between the two stocks.

BeyondSpring vs. Heron Therapeutics Stock

BeyondSpring (NASDAQ:BYSI) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for BeyondSpring and Heron Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	0	1	2	0	2.67
Heron Therapeutics	0	1	5	0	2.83

BeyondSpring presently has a consensus target price of $32.6667, suggesting a potential upside of 217.46%. Heron Therapeutics has a consensus target price of $29.60, suggesting a potential upside of 78.31%. Given BeyondSpring's higher probable upside, equities analysts clearly believe BeyondSpring is more favorable than Heron Therapeutics.

Profitability

This table compares BeyondSpring and Heron Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	-221.67%	-139.97%
Heron Therapeutics	-216.18%	-65.06%	-49.14%

Valuation & Earnings

This table compares BeyondSpring and Heron Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	$-38,080,000.00	($1.55)	-6.64
Heron Therapeutics	$145.97 million	10.39	$-204,750,000.00	($2.50)	-6.64

BeyondSpring has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

7.1% of BeyondSpring shares are held by institutional investors. Comparatively, 99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

BeyondSpring has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Summary

Heron Therapeutics beats BeyondSpring on 8 of the 13 factors compared between the two stocks.